The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CLNN | +161.6% | -95.34% | -45.83% | -95% |
| S&P | +13.14% | +87.24% | +13.37% | +135% |
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded on August 12, 2020 and is headquartered in Salt Lake City, UT.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.02M | -82.8% |
| Gross Profit | -$0.35M | -3.9% |
| Gross Margin | -2333.33% | -1946.0% |
| Market Cap | $60.67M | 104.3% |
| Market Cap / Employee | $0.80M | 0.0% |
| Employees | 76 | -10.6% |
| Net Income | -$8.78M | -9.9% |
| EBITDA | -$5.28M | 28.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.93M | -45.9% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0.1 | -52.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $19.27M | 70.9% |
| Short Term Debt | $2.04M | -82.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -113.20% | -34.9% |
| Return On Invested Capital | -229.33% | -29.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.99M | -30.8% |
| Operating Free Cash Flow | -$3.98M | -30.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -176.53 | -2.81 | -6.82 | -6.67 | -99.43% |
| Price to Sales | 125.60 | 77.66 | 130.20 | 289.56 | -79.75% |
| Price to Tangible Book Value | -176.54 | -2.81 | -6.82 | -6.67 | -99.43% |
| Enterprise Value to EBITDA | -6.26 | -10.43 | -9.24 | -14.26 | -82.68% |
| Return on Equity | -3702.2% | -289.7% | -416.9% | -1738.4% | 191.93% |
| Total Debt | $20.84M | $20.94M | $20.85M | $21.31M | -6.86% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
